BURLINGTON, Mass., Jan. 5, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11, 2023, which includes a presentation beginning at 3:45 pm PST. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
Azenta is headquartered in Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations
978.262.2635
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sherry Dinsmore
978.262.2400
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$25.50 |
| Daily Change: | -0.41 -1.58 |
| Daily Volume: | 820,392 |
| Market Cap: | US$1.170B |
November 12, 2024 November 04, 2024 October 30, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
